Skip to Main Content

Akrevia Therapeutics is on a mission to make immunotherapies safer.

The startup, based in the LabCentral incubator in Cambridge, Mass., is working on drug candidates that act much like therapies that are already on the market, including Bristol Myers-Squibb’s Yervoy and Clinigen’s Proleukin. It’s hoping it can find new drugs that mimic those effects but without sending the immune system into overdrive.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!